Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor
DOI:
https://doi.org/10.2340/actadv.v102.348Keywords:
TNF-alpha inhibitors, adalimumab, primary cutaneous B-cell lymphoma, PCBCL-LTAbstract
Abstract is missing (Short communication)
Downloads
References
Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Curr Drug Targets 2010; 11: 179-186.
https://doi.org/10.2174/138945010790309867 DOI: https://doi.org/10.2174/138945010790309867
Hruska CJ, Bertoli RJ, Young YD, Burkhart PH, Googe PB. Primary cutaneous anaplastic large cell lymphoma in a patient receiving adalimumab. JAAD Case Rep 2015; 1: 56-59.
https://doi.org/10.1016/j.jdcr.2014.12.006 DOI: https://doi.org/10.1016/j.jdcr.2014.12.006
Martinez-Escala ME, Posligua AL, Wickless H, Rutherford A, Sable KA, Rubio-Gonzalez B, et al. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2018; 78: 1068-1076.
https://doi.org/10.1016/j.jaad.2017.12.068 DOI: https://doi.org/10.1016/j.jaad.2017.12.068
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. J Crohns Colitis 2021; 15: 840-859.
https://doi.org/10.1093/ecco-jcc/jjaa186 DOI: https://doi.org/10.1093/ecco-jcc/jjaa186
Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Ghogomu ET, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015; 4: CD005468.
https://doi.org/10.1002/14651858.CD005468.pub2 DOI: https://doi.org/10.1002/14651858.CD005468.pub2
Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144-1150.
https://doi.org/10.1001/archderm.143.9.1144 DOI: https://doi.org/10.1001/archderm.143.9.1144
Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol 2014; 150: 535-541.
https://doi.org/10.1001/jamadermatol.2013.7452 DOI: https://doi.org/10.1001/jamadermatol.2013.7452
Graham PM, Richardson AS, Schapiro BL, Saunders MD, Stewart DM. Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. JAAD Case Rep 2018; 4: 305-309.
https://doi.org/10.1016/j.jdcr.2017.10.012 DOI: https://doi.org/10.1016/j.jdcr.2017.10.012
Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, et al. Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol 2009; 89: 113-117.
https://doi.org/10.1007/s12185-008-0201-5 DOI: https://doi.org/10.1007/s12185-008-0201-5
Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol 2014; 38: 999-1006.
https://doi.org/10.1097/PAS.0000000000000225 DOI: https://doi.org/10.1097/PAS.0000000000000225
Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol 2014; 150: 1173-1179.
https://doi.org/10.1001/jamadermatol.2014.821 DOI: https://doi.org/10.1001/jamadermatol.2014.821
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Samy Belkaïd, Brigitte Balme, Olivier Harou, Joann Le Borgne de la Villandré, Chloé Wirbel, Stéphane Dalle, Florent Grange
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.